iCo Therapeutics Inc. - Product Pipeline Review - 2012

Global Markets Direct, July 2012, Pages: 58

iCo Therapeutics Inc. – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “iCo Therapeutics Inc. - Product Pipeline Review - 2012” provides data on the iCo Therapeutics Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, iCo Therapeutics Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from iCo Therapeutics Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- iCo Therapeutics Inc. - Brief iCo Therapeutics Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of iCo Therapeutics Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of iCo Therapeutics Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the iCo Therapeutics Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate iCo Therapeutics Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of iCo Therapeutics Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the iCo Therapeutics Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with iCo Therapeutics Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of iCo Therapeutics Inc. and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of iCo Therapeutics Inc.; iCo Therapeutics Inc. - Key Therapeutics; iCo Therapeutics Inc. - Pipeline Overview and Promising Molecules; iCo Therapeutics Inc. - News; iCo Therapeutics Inc. - Latest Updates; iCo Therapeutics Inc. - Pipeline; iCo Therapeutics Inc. - Discontinued/Dormant Projects

2
List of Tables 4
List of Figures 4
iCo Therapeutics Inc. Snapshot 5
iCo Therapeutics Inc. Overview 5
Key Information 5
Key Facts 5
iCo Therapeutics Inc. – Research and Development Overview 6
Key Therapeutic Areas 6
iCo Therapeutics Inc. – Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products – Monotherapy 9
iCo Therapeutics Inc. – Pipeline Products Glance 10
iCo Therapeutics Inc. Clinical Stage Pipeline Products 10
Phase II Products/Combination Treatment Modalities 10
Phase I Products/Combination Treatment Modalities 11
iCo Therapeutics Inc. – Early Stage Pipeline Products 12
Pre-Clinical Products/Combination Treatment Modalities 12
iCo Therapeutics Inc. – Drug Profiles 13
iCo-007 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
iCo-008 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
iCo-009 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
iCo Therapeutics Inc. – Pipeline Analysis 18
iCo Therapeutics Inc. – Pipeline Products by Therapeutic Class 18
iCo Therapeutics Inc. – Pipeline Products By Target 19
iCo Therapeutics Inc. – Pipeline Products by Route of Administration 20
iCo Therapeutics Inc. – Pipeline Products By Mechanism of Action 21
iCo Therapeutics Inc. – Recent Pipeline Updates 22
iCo Therapeutics Inc. – Company Statement 24
iCo Therapeutics Inc. – Locations And Subsidiaries 26
Head Office 26
iCo Therapeutics Inc., Recent Developments 27
iCo Therapeutics Inc.- Press Release 27
Jul 03, 2012: Phase II Clinical Data Of iCo Therapeutics's iCo-007 Featured In JDRF's Top Research Highlights Publication 27
May 31, 2012: iCo Receives $1.1m Funding From Canadian Government To Develop Treatment For HIV/AIDS 27
Mar 28, 2012: iCo Therapeutics And JDRF Team Up To Support Phase II Clinical Trial iDEAL For Diabetic Macular Edema 28
Jan 30, 2012: IMMUNE Pharmaceuticals Receives Grant From Office Of Chief Scientist In Israel To Support Phase II Clinical Trials With Bertilimumab 29
Dec 11, 2009: iCo Therapeutics Provides Phase 1 Clinical Trial Update And Phase 2 Trial Guidance Of iCo-007 For The Treatment of DME And Diabetic Retinopathy 30
Dec 03, 2009: iCo Therapeutics Announces Study Results Of iCo-007, For The Potential Treatment of Diabetic Macular Edema and Diabetic Retinopathy 30
Jul 21, 2009: iCo Therapeutics Appoints Infectious Disease MD To Scientific Advisory Board 31
Mar 17, 2009: iCo Therapeutics iCo-007 Presents Second Cohort Results At Cleveland Clinic Ocular Conference 31
Feb 19, 2009: iCo Therapeutics iCo-007 Results To Be Presented At Prestigious Ocular Conference 31
Feb 09, 2009: iCo Therapeutics Closes $1.3 Million Private Placement 32
Financial Deals Landscape 33
iCo Therapeutics Inc., Deals Summary 33
iCo Therapeutics Inc., Pharmaceuticals & Healthcare, Deal Details 34
Asset Transactions 34
iCo Therapeutics Acquires Rights For iCo-009 From The University of British Columbia 34
Partnerships 36
iCo Therapeutics Enters Into Co-Development Agreement With JDRF For iCo-007 36
iCo Therapeutics Enters Into Technology Transfer Agreement With Isis Pharma 37
iCo Therapeutics Signs Research Agreement With Consortium for Parasitic Drug Development 38
Licensing Agreements 39
Cambridge Antibody Technology Enters Into Licensing Agreement With iCo Therapeutics 39
iCo Therapeutics Exercises Option Licensing Agreement With Immune Pharma For Bertilimumab 40
Isis Pharma Enters Into Licensing Agreement With iCo Therapeutics 42
Equity Offering 43
iCo Therapeutics Prices Public Offering Of Units For $2.5 Million 43
iCo Therapeutics Completes Non-Brokered Private Placement Of Units For $1.1 Million 45
iCo Therapeutics Announces Private Placement Of $10.4 Million 47
iCo Therapeutics Completes Private Placement Of $0.91 Million Upon Exercise Of Warrants 49
iCo Therapeutics Completes Final Tranche Private Placement Of $1.07 Million 51
iCo Therapeutics Completes Non-Brokered Private Placement Of $0.41 Million 53
iCo Therapeutics Completes Private Placement Of $1.15 Million 55
Appendix 57
Methodology 57
Coverage 57
Secondary Research 57
Primary Research 57
Expert Panel Validation 57
Contact Us 58
Disclaimer 58

List of Tables
iCo Therapeutics Inc., Key Information 5
iCo Therapeutics Inc., Key Facts 5
iCo Therapeutics Inc. – Pipeline by Indication, 2012 7
iCo Therapeutics Inc. – Pipeline by Stage of Development, 2012 8
iCo Therapeutics Inc. – Monotherapy Products in Pipeline, 2012 9
iCo Therapeutics Inc. – Phase II, 2012 10
iCo Therapeutics Inc. – Phase I, 2012 11
iCo Therapeutics Inc. – Pre-Clinical, 2012 12
iCo Therapeutics Inc. – Pipeline By Therapeutic Class, 2012 18
iCo Therapeutics Inc. - Pipeline By Target, 2012 19
iCo Therapeutics Inc. – Pipeline By Route of Administration, 2012 20
iCo Therapeutics Inc. – Pipeline Products By Mechanism of Action, 2012 21
iCo Therapeutics Inc. – Recent Pipeline Updates, 2012 22
iCo Therapeutics Inc., Deals Summary 33
iCo Therapeutics Acquires Rights For iCo-009 From The University of British Columbia 34
iCo Therapeutics Enters Into Co-Development Agreement With JDRF For iCo-007 36
iCo Therapeutics Enters Into Technology Transfer Agreement With Isis Pharma 37
iCo Therapeutics Signs Research Agreement With Consortium for Parasitic Drug Development 38
Cambridge Antibody Technology Enters Into Licensing Agreement With iCo Therapeutics 39
iCo Therapeutics Exercises Option Licensing Agreement With Immune Pharma For Bertilimumab 40
Isis Pharma Enters Into Licensing Agreement With iCo Therapeutics 42
iCo Therapeutics Prices Public Offering Of Units For $2.5 Million 43
iCo Therapeutics Completes Non-Brokered Private Placement Of Units For $1.1 Million 45
iCo Therapeutics Announces Private Placement Of $10.4 Million 47
iCo Therapeutics Completes Private Placement Of $0.91 Million Upon Exercise Of Warrants 49
iCo Therapeutics Completes Final Tranche Private Placement Of $1.07 Million 51
iCo Therapeutics Completes Non-Brokered Private Placement Of $0.41 Million 53
iCo Therapeutics Completes Private Placement Of $1.15 Million 55

List of Figures
iCo Therapeutics Inc. – Pipeline by Indication, 2012 7
iCo Therapeutics Inc. – Pipeline by Stage of Development, 2012 8
iCo Therapeutics Inc. – Monotherapy Products in Pipeline, 2012 9
iCo Therapeutics Inc. – Pipeline By Therapeutic Class, 2012 18
iCo Therapeutics Inc. - Pipeline By Target, 2012 19
iCo Therapeutics Inc. – Pipeline By Route of Administration, 2012 20

Customers who bought this item also bought

• BT Global Services Restructures In The Uk Public Sector
• Logica in UK Public Sector: Must Build on Strong Foundations
• UK - Capita - Company Profile
• UK - Logica - Company Profile
• Atos - Profile - UK
• UK - Steria - Company Profile
• UK - IBM - Company Profile
• UK - Capgemini - Company Profile
• UK - Unisys - Company Profile
• CSC - Profile - UK